What is Alnylam Pharmaceuticals, Inc.'s earnings per share (EPS)?

Alnylam Pharmaceuticals, Inc. (ALNY) reported diluted earnings per share of $2.33 for fiscal year 2025. This represents a 206.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Alnylam Pharmaceuticals, Inc. (ALNY) Financials

ALNY

FY2025 annual

Revenue $3.7B +65.2% YoY

Net Income $313.7M +212.8% YoY

EPS (Diluted) $2.33 +206.9% YoY

Free Cash Flow $465.4M +1192.7% YoY

Market Cap $29.9B as of Oct 13, 2026

Price / Sales 8.1x on $3.7B revenue, FY2025

Price / Earnings 95.5x on $313.7M net income, FY2025

Price / Book 22.1x on $1.4B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALNY SEC filings page.

Alnylam Pharmaceuticals, Inc. (ALNY) reported $3.7B in revenue for fiscal year 2025, up 65.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ALNY FY2025 2026-10-04

After years of heavy investment, Alnylam’s 2025 scale finally converted into operating profit and cash while gross margin became less exceptional.

In FY2025, a 13.5% operating margin coincided with operating cash flow of $524M, after FY2024 cash generation was nearly flat. The earnings improvement therefore reached cash rather than remaining an accounting result, indicating a meaningful change in operating economics.

Despite a lower gross margin in FY2025, operating margin reached 13.5%; because R&D and SG&A still rose in absolute terms, the change points to revenue scale absorbing operating costs rather than simple cost cutting.

FY2025 free cash flow of $465M was close to operating cash flow of $524M, showing that capital spending consumed relatively little internally generated cash. After negative equity in FY2023, equity was positive in FY2025, but reported debt-to-equity remained 5.3x; improved profitability repaired book capital without making the financing structure light.

Financial Health Signals

Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Alnylam Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Alnylam Pharmaceuticals, Inc. has an operating margin of 13.5%, meaning the company retains $14 of operating profit per $100 of revenue. This results in a moderate score of 36/100, indicating healthy but not exceptional operating efficiency. This is up from -7.9% the prior year.

Growth

Alnylam Pharmaceuticals, Inc.'s revenue surged 65.2% year-over-year to $3.7B, reflecting rapid business expansion. This strong growth earns a score of 93/100.

Leverage

Alnylam Pharmaceuticals, Inc. has elevated debt relative to equity (D/E of 5.29), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 11/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.76, Alnylam Pharmaceuticals, Inc. holds $2.76 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Cash Flow

Alnylam Pharmaceuticals, Inc. has a free cash flow margin of 12.5%, earning a moderate score of 50/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Alnylam Pharmaceuticals, Inc.'s ROE of 39.8% shows moderate profitability relative to equity, earning a score of 38/100. This is up from -414.6% the prior year.

Altman Z-Score Safe

4.12

Alnylam Pharmaceuticals, Inc. scores 4.12, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($29.9B) relative to total liabilities ($4.2B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Alnylam Pharmaceuticals, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.67x

For every $1 of reported earnings, Alnylam Pharmaceuticals, Inc. generates $1.67 in operating cash flow ($524.1M OCF vs $313.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.99x

Alnylam Pharmaceuticals, Inc. earns $1.99 in operating income for every $1 of interest expense ($501.6M vs $252.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.3B

YoY+66.9%

Alnylam Pharmaceuticals, Inc. generated $1.3B in revenue in Q2 2026. This represents an increase of 66.9% from the same quarter a year earlier.

Net Income

$164.5M

YoY+327.7%

QoQ-20.1%

Alnylam Pharmaceuticals, Inc. reported $164.5M in net income in Q2 2026. This represents an increase of 327.7% from the same quarter a year earlier. Against the prior quarter it is down 20.1%.

EPS (Diluted)

$1.21

YoY+320.0%

Alnylam Pharmaceuticals, Inc. earned $1.21 per diluted share (EPS) in Q2 2026. This represents an increase of 320.0% from the same quarter a year earlier.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$1.7B

YoY+53.4%

Alnylam Pharmaceuticals, Inc. held $1.7B in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

134M

YoY+2.1%

QoQ0.0%

5Y CAGR+2.4%

10Y CAGR+4.6%

Alnylam Pharmaceuticals, Inc. had 134M shares outstanding in Q2 2026. This represents an increase of 2.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

76.9%

YoY-4.7pp

Alnylam Pharmaceuticals, Inc.'s gross margin was 76.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 4.7 percentage points from the same quarter a year earlier.

Operating Margin

17.9%

YoY+20.0pp

Alnylam Pharmaceuticals, Inc.'s operating margin was 17.9% in Q2 2026, reflecting core business profitability. This is up 20.0 percentage points from the same quarter a year earlier.

Net Margin

12.7%

YoY+22.1pp

Alnylam Pharmaceuticals, Inc.'s net profit margin was 12.7% in Q2 2026, showing the share of revenue converted to profit. This is up 22.1 percentage points from the same quarter a year earlier.

Return on Equity

12.2%

YoY+25.2pp

QoQ-7.0pp

Alnylam Pharmaceuticals, Inc.'s ROE was 12.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 25.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.0 percentage points.

Capital Allocation

R&D Spending

$413.1M

YoY+27.7%

Alnylam Pharmaceuticals, Inc. invested $413.1M in research and development in Q2 2026. This represents an increase of 27.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ALNY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALNY quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.7B+65.2%	$2.2B+23.0%	$1.8B+76.2%	$1.0B+22.9%	$844.3M+71.3%	$492.9M+124.3%	$219.8M+193.4%	$74.9M-16.7%	$89.9M+90.7%	$47.2M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$677.2M+120.9%	$306.5M+14.3%	$268.2M+91.3%	$140.2M+21.9%	$115.0M+55.0%	$74.2M+196.0%	$25.1M+1290.8%	$1.8M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$3.0B+56.4%	$1.9B+24.5%	$1.6B+73.9%	$897.2M+23.0%	$729.3M+74.2%	$418.7M+115.0%	$194.7M+166.3%	$73.1M-18.7%	$89.9M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.3B+17.2%	$1.1B+12.1%	$1.0B+13.7%	$883.0M+11.5%	$792.2M+21.0%	$654.8M0.0%	$655.1M+29.6%	$505.4M+29.4%	$390.6M+2.2%	$382.4M+38.3%	$276.5M+45.3%	$190.2M+68.4%	$113.0M+30.5%	$86.6M-12.8%	$99.3M
SG&A Expenses	$1.2B+24.1%	$975.5M+22.6%	$795.6M+3.2%	$770.7M+24.2%	$620.6M+5.5%	$588.4M+22.8%	$479.0M+25.3%	$382.4M+91.8%	$199.4M+123.1%	$89.4M+47.4%	$60.6M+36.1%	$44.5M+64.0%	$27.2M-39.1%	$44.6M+16.5%	$38.3M
Operating Income	$501.6M+383.6%	-$176.9M+37.3%	-$282.2M+64.1%	-$785.1M-10.8%	-$708.7M+14.5%	-$828.4M+11.8%	-$939.4M-15.3%	-$814.7M-62.9%	-$500.1M-17.8%	-$424.6M-43.4%	-$296.0M+26.9%	-$405.0M-335.7%	-$92.9M+28.2%	-$129.5M-136.2%	-$54.8M
EBITDA	$557.2M+563.5%	-$120.2M+47.3%	-$228.1M+69.2%	-$740.6M-12.0%	-$661.1M+16.7%	-$793.7M+13.9%	-$922.3M-15.4%	-$799.4M-64.2%	-$486.7M-18.9%	-$409.5M-47.8%	-$277.0M+29.5%	-$393.1M-375.2%	-$82.7M+31.3%	-$120.4M-142.3%	-$49.7M
Interest Expense	$252.6M+78.1%	$141.9M+17.0%	$121.2M-22.3%	$156.0M+9.1%	$143.0M+69.3%	$84.5M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$9.4M+109.5%	-$99.2M-1575.4%	$6.7M+61.5%	$4.2M+512.2%	$680K-74.6%	$2.7M+210.7%	$863K+4.9%	$823K	$0	$0	$0+100.0%	-$40.2M-1392.0%	-$2.7M+74.5%	-$10.6M	$0
Net Income	$313.7M+212.8%	-$278.2M+36.8%	-$440.2M+61.1%	-$1.1B-32.6%	-$852.8M+0.6%	-$858.3M+3.1%	-$886.1M-16.4%	-$761.5M-55.1%	-$490.9M-19.7%	-$410.1M-41.4%	-$290.1M+19.5%	-$360.4M-303.9%	-$89.2M+15.8%	-$106.0M-83.9%	-$57.6M
EPS (Basic)	$2.39+209.6%	-$2.18+38.1%	-$3.52+62.2%	-$9.30-29.2%	-$7.20+3.5%	-$7.46+8.0%	-$8.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$2.33+206.9%	-$2.18+38.1%	-$3.52+62.2%	-$9.30-29.2%	-$7.20+3.5%	-$7.46+8.0%	-$8.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	135M+5.5%	128M+2.2%	125M+2.6%	122M+2.7%	118M+3.0%	115M+5.2%	109M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.3B+66.9%	N/A	N/A	$1.2B+149.3%	$773.7M+17.3%	N/A	$593.2M+34.9%	$500.9M-33.3%
Cost of Revenue	$298.3M+110.0%	N/A	N/A	$197.2M+140.6%	$142.0M+111.1%	N/A	$102.6M+42.6%	$82.0M+3.2%
Gross Profit	$992.7M+57.2%	N/A	N/A	$1.1B+151.1%	$631.7M+6.6%	N/A	$490.5M+33.4%	$418.9M-37.6%
R&D Expenses	$413.1M+27.7%	N/A	N/A	$358.8M+32.4%	$323.6M+10.0%	N/A	$300.2M+10.3%	$270.9M+7.0%
SG&A Expenses	$347.9M+7.6%	N/A	N/A	$322.1M+45.7%	$323.3M+30.2%	N/A	$295.3M+49.1%	$221.0M+11.0%
Operating Income	$231.4M+1528.7%	N/A	N/A	$368.0M+578.5%	-$16.2M-133.3%	N/A	-$105.2M+9.7%	-$76.9M-136.0%
EBITDA	N/A	N/A	N/A	$381.8M+706.7%	N/A	N/A	-$91.0M+11.6%	-$62.9M-127.7%
Interest Expense	$82.1M+33.5%	N/A	N/A	$44.4M+29.2%	$61.5M+84.8%	N/A	$39.0M+24.4%	$34.4M+11.3%
Income Tax	$13.3M-56.9%	N/A	N/A	-$12.1M-516.8%	$30.9M+440.4%	N/A	-$110.2M-60315.8%	$2.9M-2.7%
Net Income	$164.5M+327.7%	$206.0M+1228.7%	N/A	$251.1M+325.0%	-$72.2M-327.7%	-$18.3M+72.3%	-$83.8M+39.2%	-$111.6M-175.5%
EPS (Basic)	$1.23+323.6%	N/A	$0.84+229.2%	$1.91+319.5%	-$0.55-323.1%	N/A	-$0.65+40.4%	-$0.87-173.7%
EPS (Diluted)	$1.21+320.0%	N/A	$0.82+226.2%	$1.84+311.5%	-$0.55-323.1%	N/A	-$0.65+40.4%	-$0.87-175.7%
Diluted Shares (Avg)	138M+5.9%	N/A	N/A	137M+6.8%	131M+3.1%	N/A	N/A	129M-2.1%

ALNY Balance Sheet

ALNY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.0B+17.1%	$4.2B+10.7%	$3.8B+8.0%	$3.5B-2.7%	$3.6B+6.9%	$3.4B+42.2%	$2.4B+52.1%	$1.6B-21.1%	$2.0B+58.0%	$1.3B-8.9%	$1.4B+28.4%	$1.1B+156.7%	$420.5M+46.3%	$287.5M+2.0%	$281.9M
Current Assets	$4.1B+22.9%	$3.3B+10.5%	$3.0B+10.8%	$2.7B-4.1%	$2.8B+7.4%	$2.6B+52.4%	$1.7B+42.9%	$1.2B-32.0%	$1.8B+162.7%	$671.9M-39.2%	$1.1B+48.1%	$746.4M+193.8%	$254.0M+102.3%	$125.6M-17.4%	$152.0M
Cash & Equivalents	$1.7B+71.5%	$966.4M+18.9%	$812.7M-6.2%	$866.4M+5.7%	$820.0M+65.1%	$496.6M-9.2%	$547.2M+30.2%	$420.1M-34.9%	$645.4M+233.3%	$193.6M+7.0%	$180.9M+140.6%	$75.2M+41.4%	$53.2M+3.4%	$51.4M-26.8%	$70.2M
Short-Term Investments	$1.3B-27.3%	$1.7B+6.5%	$1.6B+24.5%	$1.3B-16.2%	$1.5B+16.2%	$1.3B+36.7%	$975.0M+47.1%	$662.8M-36.6%	$1.0B+146.4%	$424.2M-50.0%	$848.2M+61.0%	$526.9M+173.4%	$192.7M+169.9%	$71.4M-6.3%	$76.2M
Inventory	$82.7M+5.4%	$78.5M-11.9%	$89.1M-30.9%	$129.0M+49.3%	$86.4M+14.8%	$75.2M+33.5%	$56.3M+134.1%	$24.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$777.6M+91.8%	$405.3M+23.6%	$327.8M+37.7%	$238.0M+19.8%	$198.6M+93.9%	$102.4M+138.1%	$43.0M+129.3%	$18.8M-44.8%	$34.0M	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$13.9M-95.7%	$324.8M+29.0%	$251.8M-10.0%	$279.8M+167.5%	$104.6M+1.1%	$103.4M-9.6%	$114.4M
Total Liabilities	$4.2B+0.1%	$4.2B+3.0%	$4.1B+9.3%	$3.7B+21.3%	$3.1B+27.8%	$2.4B+150.0%	$956.4M+250.6%	$272.8M+19.5%	$228.3M-33.4%	$342.6M+181.3%	$121.8M-15.0%	$143.3M-4.6%	$150.2M-2.1%	$153.5M-6.4%	$163.9M
Current Liabilities	$1.5B+23.6%	$1.2B+22.6%	$967.8M+26.0%	$767.9M+10.4%	$695.7M+18.9%	$585.3M+66.0%	$352.6M+96.4%	$179.5M+24.4%	$144.3M+9.5%	$131.7M+112.1%	$62.1M-34.9%	$95.3M+77.0%	$53.9M+11.4%	$48.3M-40.3%	$81.0M
Non-Current Liabilities	$2.7B-9.2%	$3.0B-3.1%	$3.1B+5.0%	$2.9B+24.5%	$2.4B+30.7%	$1.8B+199.0%	$603.8M+546.9%	$93.3M+11.1%	$84.0M-60.1%	$210.9M+253.3%	$59.7M+24.4%	$48.0M-50.2%	$96.3M-8.4%	$105.1M+26.8%	$82.9M
Long-Term Debt	N/A	N/A	N/A	N/A	$675.7M+253.3%	$191.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$789.2M+1076.3%	$67.1M+130.4%	-$220.6M-39.5%	-$158.2M-126.9%	$588.2M-42.1%	$1.0B-29.4%	$1.4B+10.5%	$1.3B-26.3%	$1.8B+92.0%	$920.2M-27.2%	$1.3B+35.1%	$936.3M+246.3%	$270.3M+101.7%	$134.1M+13.6%	$118.0M
Retained Earnings	-$6.7B+8.0%	-$7.3B-4.0%	-$7.0B-6.7%	-$6.6B-20.8%	-$5.4B-18.6%	-$4.6B-23.0%	-$3.7B-31.2%	-$2.8B-32.3%	-$2.1B-29.6%	-$1.7B-32.9%	-$1.2B-30.3%	-$956.6M-60.4%	-$596.2M-17.6%	-$507.0M-26.4%	-$401.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.6B+21.7%	N/A	$5.0B+17.1%	$4.9B+15.4%	$4.6B+13.9%	$4.2B+10.2%	$4.2B+10.7%	$4.2B+9.5%
Current Assets	$4.6B+26.8%	N/A	$4.1B+22.9%	$4.0B+17.8%	$3.6B+14.8%	$3.3B+9.4%	$3.3B+10.5%	$3.4B+12.4%
Cash & Equivalents	$1.7B+53.4%	N/A	$1.7B+71.5%	$1.5B+35.5%	$1.1B+15.0%	N/A	$966.4M+18.9%	$1.1B+6.5%
Short-Term Investments	$1.6B-8.3%	N/A	$1.3B-27.3%	$1.2B-26.2%	$1.7B+5.9%	$1.6B-4.3%	$1.7B+6.5%	$1.7B+22.7%
Inventory	$97.1M+35.5%	N/A	$82.7M+5.4%	$75.4M-0.8%	$71.7M-14.6%	$65.6M-30.2%	$78.5M-11.9%	$76.0M-20.7%
Accounts Receivable	$912.7M+60.9%	N/A	$777.6M+91.8%	$964.8M+172.6%	$567.1M+83.2%	$418.0M+30.1%	$405.3M+23.6%	$353.9M+8.7%
Long-Term Investments	$0	N/A	$0	$0	$0	N/A	$0	$0
Total Liabilities	$4.2B-2.6%	N/A	$4.2B+0.1%	$4.6B+10.7%	$4.3B+7.5%	$4.1B+1.4%	$4.2B+3.0%	$4.2B+4.2%
Current Liabilities	$1.5B+16.3%	N/A	$1.5B+23.6%	$1.6B+27.4%	$1.3B+23.3%	$1.1B+14.2%	$1.2B+22.6%	$1.2B+28.5%
Non-Current Liabilities	$2.7B-10.7%	N/A	$2.7B-9.2%	$3.1B+3.7%	$3.0B+1.9%	$3.0B-2.6%	$3.0B-3.1%	$3.0B-3.4%
Total Equity	$1.4B+143.8%	$1.1B+152.4%	$789.2M+1076.3%	$233.9M+622.9%	$555.3M+18207.1%	$426.1M+294.3%	$67.1M+130.4%	$32.4M+119.5%
Retained Earnings	-$6.3B+14.6%	N/A	-$6.7B+8.0%	-$7.2B+0.6%	-$7.4B-4.5%	-$7.3B-3.8%	-$7.3B-4.0%	-$7.2B-4.8%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ALNY Cash Flow Statement

ALNY quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$524.1M+6405.1%	-$8.3M-108.0%	$104.2M+119.2%	-$541.3M+15.6%	-$641.7M-4.3%	-$615.0M-120.9%	-$278.4M+50.5%	-$562.6M-47.0%	-$382.8M-24.4%	-$307.7M-62.7%	-$189.1M-14.2%	-$165.6M-141.3%	-$68.7M+40.6%	-$115.6M-32.8%	-$87.1M
Depreciation & Amortization	$55.7M-1.8%	$56.7M+4.8%	$54.1M+21.6%	$44.5M-6.5%	$47.6M+36.8%	$34.8M+102.5%	$17.2M+12.6%	$15.2M+14.1%	$13.4M-11.7%	$15.1M-20.6%	$19.1M+59.7%	$11.9M+16.6%	$10.2M+13.2%	$9.0M+76.3%	$5.1M
Stock-Based Compensation	$348.2M+28.0%	$272.1M+22.7%	$221.7M-3.9%	$230.6M+39.2%	$165.7M+18.5%	$139.9M-20.0%	$174.8M+10.8%	$157.8M+70.0%	$92.8M+22.9%	$75.5M+65.0%	$45.8M+38.5%	$33.1M+59.7%	$20.7M+67.5%	$12.4M-25.9%	$16.7M
Capital Expenditures	$58.7M+71.2%	$34.3M-44.9%	$62.2M-13.7%	$72.1M-5.6%	$76.4M+8.5%	$70.4M-49.8%	$140.2M+10.5%	$126.9M+21.8%	$104.2M+61.4%	$64.6M+398.5%	$12.9M+44.5%	$9.0M+123.7%	$4.0M-52.0%	$8.3M+546.6%	$1.3M
Free Cash Flow	$465.4M+1192.7%	-$42.6M-201.5%	$41.9M+106.8%	-$613.3M+14.6%	-$718.1M-4.8%	-$685.3M-63.7%	-$418.6M+39.3%	-$689.5M-41.6%	-$487.0M-30.8%	-$372.3M-84.2%	-$202.1M-15.7%	-$174.6M-140.3%	-$72.7M+41.4%	-$124.0M-40.3%	-$88.4M
Investing Cash Flow	$436.3M+473.4%	-$116.8M+65.3%	-$336.4M-298.6%	$169.4M+162.0%	-$273.3M+37.2%	-$435.5M-4.3%	-$417.7M-253.0%	$272.9M+194.0%	-$290.4M-303.6%	$142.6M	N/A	N/A	-$130.5M-3968.0%	$3.4M-95.9%	$82.0M
Financing Cash Flow	-$305.2M-203.8%	$294.2M+70.9%	$172.1M-59.6%	$425.8M-65.9%	$1.2B+25.3%	$995.0M+20.9%	$823.2M+1157.3%	$65.5M-94.2%	$1.1B+532.6%	$177.8M	N/A	N/A	$200.9M+115.1%	$93.4M+12557.5%	$738K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	N/A	N/A	$163.6M+272.8%	$351.0M+703.1%	N/A	N/A	-$94.7M-217.7%	$43.7M-87.8%
Depreciation & Amortization	N/A	N/A	$13.5M-4.7%	$13.8M-1.3%	N/A	N/A	$14.2M+5.1%	$14.0M+4.9%
Stock-Based Compensation	$86.6M-22.4%	N/A	N/A	$108.2M+136.2%	$111.7M+25.1%	N/A	N/A	$45.8M-28.4%
Capital Expenditures	N/A	N/A	$23.3M+156.1%	$12.1M+189.6%	N/A	N/A	$9.1M-40.6%	$4.2M-75.5%
Free Cash Flow	N/A	N/A	$140.3M+235.2%	$338.9M+757.6%	N/A	N/A	-$103.8M-130.0%	$39.5M-88.5%
Investing Cash Flow	N/A	N/A	-$37.2M+29.8%	$501.1M+1756.6%	N/A	N/A	-$52.9M+78.0%	-$30.3M-181.0%
Financing Cash Flow	N/A	N/A	$45.3M+46.2%	-$474.3M-561.6%	N/A	N/A	$31.0M-21.0%	$102.8M+210.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ALNY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALNY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	81.8%-4.6pp	86.4%+1.0pp	85.3%-1.2pp	86.5%+0.1pp	86.4%+1.4pp	85.0%-3.6pp	88.6%-9.0pp	97.6%-2.4pp	100.0%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	13.5%+21.4pp	-7.9%+7.6pp	-15.4%+60.3pp	-75.7%+8.3pp	-83.9%	-168.1%	-427.5%	-1087.6%	-556.2%	-900.3%	N/A	N/A	N/A	N/A	N/A
Net Margin	8.5%+20.8pp	-12.4%+11.7pp	-24.1%	-109.0%	-101.0%	-174.2%	-403.2%	-1016.6%	-546.0%	-869.6%	N/A	N/A	N/A	N/A	N/A
Return on Equity	39.8%+454.4pp	-414.6%	N/A	N/A	-145.0%-60.5pp	-84.5%-22.9pp	-61.6%-3.1pp	-58.5%-30.7pp	-27.8%+16.8pp	-44.6%-21.6pp	-22.9%+15.6pp	-38.5%-5.5pp	-33.0%+46.1pp	-79.1%-30.2pp	-48.9%
Return on Assets	6.3%+12.9pp	-6.6%+4.9pp	-11.5%+20.4pp	-31.9%-8.5pp	-23.4%+1.8pp	-25.2%+11.8pp	-37.0%+11.4pp	-48.4%-23.7pp	-24.6%+7.9pp	-32.5%-11.6pp	-20.9%+12.5pp	-33.4%-12.2pp	-21.2%+15.7pp	-36.9%-16.4pp	-20.4%
Current Ratio	2.760.0x	2.78-0.3x	3.08-0.4x	3.51-0.5x	4.04-0.4x	4.47-0.4x	4.87-1.8x	6.69-5.5x	12.23+7.1x	5.10-12.7x	17.80+10.0x	7.83+3.1x	4.72+2.1x	2.60+0.7x	1.88
Debt-to-Equity	5.29-56.9x	62.20	N/A	N/A	1.15+1.0x	0.19-0.5x	0.66+0.5x	0.21+0.1x	0.13-0.2x	0.37+0.3x	0.10-0.1x	0.15-0.4x	0.56-0.6x	1.14-0.2x	1.39
Asset Turnover	0.75+0.2x	0.53+0.1x	0.48+0.2x	0.29+0.1x	0.23+0.1x	0.14+0.1x	0.090.0x	0.050.0x	0.050.0x	0.04	N/A	N/A	N/A	N/A	N/A
FCF Margin	12.5%+14.4pp	-1.9%-4.2pp	2.3%+61.4pp	-59.1%+25.9pp	-85.0%	-139.1%	-190.5%	-920.5%	-541.6%	-789.4%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	76.9%-4.7pp	N/A	N/A	84.2%+0.6pp	81.6%-8.2pp	N/A	82.7%-0.9pp	83.6%-5.8pp
Operating Margin	17.9%+20.0pp	N/A	N/A	29.5%+44.8pp	-2.1%-9.5pp	N/A	-17.7%+8.7pp	-15.3%-43.9pp
Net Margin	12.7%+22.1pp	N/A	N/A	20.1%+42.4pp	-9.3%-6.8pp	N/A	-14.1%+17.2pp	-22.3%-42.0pp
Return on Equity	12.2%+25.2pp	19.2%+23.4pp	N/A	107.3%+452.2pp	-13.0%	-4.3%	-124.9%	-344.8%
Return on Assets	3.0%+4.5pp	N/A	N/A	5.2%+7.8pp	-1.6%-1.2pp	-0.4%+1.3pp	-2.0%+1.6pp	-2.6%-6.5pp
Current Ratio	3.05+0.3x	N/A	2.760.0x	2.54-0.2x	2.80-0.2x	3.04-0.1x	2.78-0.3x	2.75-0.4x
Debt-to-Equity	3.11-4.7x	N/A	5.29-56.9x	19.74-109.2x	7.77	9.62	62.20	128.97
Asset Turnover	0.23+0.1x	N/A	N/A	0.26+0.1x	0.170.0x	N/A	0.140.0x	0.12-0.1x
FCF Margin	N/A	N/A	N/A	27.1%+19.2pp	N/A	N/A	-17.5%-7.2pp	7.9%-37.7pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Alnylam Pharmaceuticals, Inc. ALNY	FY2025	$3.7B	$313.7M	8.5%	$29.9B	51/100
Regeneron Pharmaceuticals Inc REGN	FY2025	$14.3B	$4.5B	31.4%	$78.5B	78/100
Vertex Pharmaceuticals Inc VRTX	FY2025	$12.0B	$4.0B	32.9%	$128.5B	74/100
argenx SE ARGX	FY2025	$4.2B	$1.3B	30.4%	$51.1B	43/100
BeOne Medicines Ltd. ONC	FY2025	$5.3B	$286.9M	5.4%	$39.6B	57/100
Insmed, Inc. INSM	FY2025	$606.4M	-$1.3B	N/A	$21.5B	51/100

Where Alnylam Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Alnylam Pharmaceuticals, Inc.'s annual revenue?

Alnylam Pharmaceuticals, Inc. (ALNY) reported $3.7B in total revenue for fiscal year 2025. This represents a 65.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alnylam Pharmaceuticals, Inc.'s revenue growing?

Alnylam Pharmaceuticals, Inc. (ALNY) revenue grew by 65.2% year-over-year, from $2.2B to $3.7B in fiscal year 2025.

Is Alnylam Pharmaceuticals, Inc. profitable?

Yes, Alnylam Pharmaceuticals, Inc. (ALNY) reported a net income of $313.7M in fiscal year 2025, with a net profit margin of 8.5%.

What is Alnylam Pharmaceuticals, Inc.'s EBITDA?

Alnylam Pharmaceuticals, Inc. (ALNY) had EBITDA of $557.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Alnylam Pharmaceuticals, Inc.'s gross margin?

Alnylam Pharmaceuticals, Inc. (ALNY) had a gross margin of 81.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Alnylam Pharmaceuticals, Inc.'s operating margin?

Alnylam Pharmaceuticals, Inc. (ALNY) had an operating margin of 13.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Alnylam Pharmaceuticals, Inc.'s net profit margin?

Alnylam Pharmaceuticals, Inc. (ALNY) had a net profit margin of 8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Alnylam Pharmaceuticals, Inc.'s return on equity (ROE)?

Alnylam Pharmaceuticals, Inc. (ALNY) has a return on equity of 39.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Alnylam Pharmaceuticals, Inc.'s free cash flow?

Alnylam Pharmaceuticals, Inc. (ALNY) generated $465.4M in free cash flow during fiscal year 2025. This represents a 1192.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alnylam Pharmaceuticals, Inc.'s operating cash flow?

Alnylam Pharmaceuticals, Inc. (ALNY) generated $524.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Alnylam Pharmaceuticals, Inc.'s total assets?

Alnylam Pharmaceuticals, Inc. (ALNY) had $5.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Alnylam Pharmaceuticals, Inc.'s capital expenditures?

Alnylam Pharmaceuticals, Inc. (ALNY) invested $58.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Alnylam Pharmaceuticals, Inc. spend on research and development?

Alnylam Pharmaceuticals, Inc. (ALNY) invested $1.3B in research and development during fiscal year 2025.

How many shares does Alnylam Pharmaceuticals, Inc. have outstanding?

Alnylam Pharmaceuticals, Inc. (ALNY) had 133M shares outstanding as of fiscal year 2025.

What is Alnylam Pharmaceuticals, Inc.'s current ratio?

Alnylam Pharmaceuticals, Inc. (ALNY) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.

What is Alnylam Pharmaceuticals, Inc.'s debt-to-equity ratio?

Alnylam Pharmaceuticals, Inc. (ALNY) had a debt-to-equity ratio of 5.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alnylam Pharmaceuticals, Inc.'s return on assets (ROA)?

Alnylam Pharmaceuticals, Inc. (ALNY) had a return on assets of 6.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?

Alnylam Pharmaceuticals, Inc. (ALNY) trades at 95.5x earnings, its market capitalization divided by net income of $313.7M net income, FY2025. The market capitalization is $29.9B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Alnylam Pharmaceuticals, Inc.'s price-to-sales ratio?

Alnylam Pharmaceuticals, Inc. (ALNY) trades at 8.1x sales, its market capitalization divided by revenue of $3.7B revenue, FY2025. The market capitalization is $29.9B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Alnylam Pharmaceuticals, Inc.'s Altman Z-Score?

Alnylam Pharmaceuticals, Inc. (ALNY) has an Altman Z-Score of 4.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Alnylam Pharmaceuticals, Inc.'s Piotroski F-Score?

Alnylam Pharmaceuticals, Inc. (ALNY) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alnylam Pharmaceuticals, Inc.'s earnings high quality?

Alnylam Pharmaceuticals, Inc. (ALNY) has an earnings quality ratio of 1.67x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Alnylam Pharmaceuticals, Inc. cover its interest payments?

Alnylam Pharmaceuticals, Inc. (ALNY) has an interest coverage ratio of 1.99x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. (ALNY) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.